Abstract
There are no clear criteria for antifungal de-escalation after initial empirical treatments. We hypothesized that early de-escalation (ED) (within 5 days) to fluconazole is safe in fluconazole-susceptible candidemia with controlled source of infection. This is a multicenter post hoc study that included consecutive patients from 3 prospective candidemia cohorts (2007-2016). The impact of ED and factors associated with mortality were assessed. Of 1023 candidemia episodes, 235 met inclusion criteria. Of these, 54 (23%) were classified as the ED group and 181 (77%) were classified as the non-ED group. ED was more common in catheter-related candidemia (51.9% vs 31.5%; P = .006) and episodes caused by Candida parapsilosis, yet it was less frequent in patients in the intensive care unit (24.1% vs 39.2%; P = .043), infections caused by Nakaseomyces glabrata (0% vs 9.9%; P = .016), and candidemia from an unknown source (24.1% vs 47%; P = .003). In the ED and non-ED groups, 30-day mortality was 11.1% and 29.8% (P = .006), respectively. Chronic obstructive pulmonary disease (odds ratio [OR], 3.97; 95% confidence interval [CI], 1.48-10.61), Pitt score > 2 (OR, 4.39; 95% CI, 1.94-9.20), unknown source of candidemia (OR, 2.59; 95% CI, 1.14-5...Continue Reading
References
Oct 15, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Olafur GudlaugssonDaniel Diekema
Sep 24, 2008·Antimicrobial Agents and Chemotherapy·Luis Ostrosky-ZeichnerThomas J Walsh
May 16, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David L HornKaren M Webster
Dec 1, 2010·Antimicrobial Agents and Chemotherapy·Michael A PfallerMariana Castanheira
Dec 21, 2010·Critical Care Medicine·Daniel H KettUNKNOWN Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators
Jan 4, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·O A CornelyUNKNOWN ESCMID Fungal Infection Study Group
Sep 6, 2013·Journal of Medical Economics·Robert G MastertonIsaac A O Odeyemi
Dec 18, 2013·International Journal of Clinical Practice·A M BalM McGill
Dec 25, 2013·Antimicrobial Agents and Chemotherapy·Jesús GuineaUNKNOWN CANDIPOP Project, GEIH-GEMICOMED (SEIMC), and REIPI
Feb 25, 2014·BMC Infectious Diseases·Jose VazquezRobert Swanson
Mar 15, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·G CuervoUNKNOWN CANDIPOP project and the validation cohort project
Sep 16, 2015·Intensive Care Medicine·Sébastien BaillyJean-François Timsit
Oct 16, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·G CuervoJ Carratalà
Dec 19, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter G PappasJack D Sobel
Dec 29, 2015·Mycoses·Patrick J van der GeestA B Johan Groeneveld
Dec 1, 2017·Critical Care Medicine·José Garnacho-MonteroJosé Luis García-Garmendia
Oct 6, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Bart Jan KullbergGeorge R Thompson